As per MRFR analysis, the Glucagen Injection market size was estimated at 0.24 (USD billion) in 2022. The Glucagen Injection market is expected to grow from 0.25 (USD billion) in 2023 to 0.41 (USD billion) by 2032. The Glucagen Injection Market CAGR (growth rate) is expected to be around 5.63% during the forecast period (2024-2032). An increase in patient education and awareness and increasing technological innovations are the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market access and affordability play a crucial role in driving the Glucagen injection market by ensuring widespread availability and accessibility of this life-saving emergency treatment for severe hypoglycemia. Efforts to enhance patient access involve collaborations with healthcare systems, insurance providers, and patient assistance programs. Initiatives to make Glucagen more affordable for individuals with diabetes contribute to increased adoption. As affordability barriers decrease, more patients and caregivers can obtain and utilize Glucagen, promoting its use in emergency situations. This focus on accessibility aligns with the broader goal of improving diabetes care and patient outcomes, shaping the Glucagen injection market and reinforcing its position as a critical intervention in managing severe hypoglycemia.
The increase in patient education and awareness is driving the Glucagen injection market by fostering a better understanding of the importance of emergency hypoglycemia management. Educational initiatives aimed at healthcare professionals and patients emphasize the role of Glucagen in severe hypoglycemia situations, empowering individuals and caregivers to respond effectively. Awareness campaigns highlight the significance of having Glucagen readily available and the proper administration techniques. As knowledge spreads, there is an elevated recognition of Glucagen's role in diabetes care, driving increased prescriptions and adoption. The concerted efforts to educate and raise awareness contribute to a proactive approach in managing severe hypoglycemia, ultimately propelling the growth of the Glucagen injection market.
The increase in technological advances is driving the Glucagen injection market by fostering innovation in delivery methods and formulations. Ongoing research and development focus on creating more sophisticated and user-friendly devices for administering glucagon during severe hypoglycemic episodes. Advanced technologies may lead to the development of novel formulations, improving stability and ease of use. These technological advancements address existing limitations and enhance the overall patient experience, driving increased adoption of Glucagen. As technological innovation continues, the market benefits from improved product efficacy, streamlined administration processes, and heightened patient confidence, solidifying Glucagen's role as a vital emergency treatment for severe hypoglycemia in the evolving landscape of diabetes care.
For instance, as reported by the International Diabetes Federation (IDF), the global adult diabetes population is estimated to be around 537 million in 2021, with a projected increase to 643 million by the year 2030. Thus, driving the Glucagen Injection market revenue.
The Glucagen Injection Market segmentation, based on application includes Therapeutic purpose and Diagnostics purpose. The Therapeutic purpose segment dominated the market, accounting for 60% of market revenue (xx Billion). In developing economies, category growth is driven by an expanding overweight population and increased consumer knowledge of low-calorie beverages. Therapeutic purpose applications have secured the largest market share in the Glucagen Injection market due to their critical role in emergency treatment for severe hypoglycemia and diagnostic procedures. Glucagen Injections are widely utilized in clinical settings, emergency response, and hospital environments to swiftly elevate blood sugar levels. Their vital role in managing hypoglycemic episodes and facilitating medical diagnostics has positioned therapeutic purpose applications as the preferred choice, driving their dominance in the market for Glucagen Injections.
Diagnostics purpose applications are experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to their increasing adoption for medical imaging procedures such as MRI scans. The use of Glucagen Injections as a contrast agent in diagnostic imaging has expanded their application, leading to a notable rise in demand. The versatility of Glucagen Injections for diagnostic purposes, particularly in radiology and imaging, has contributed to their substantial CAGR growth within the market for contrast agents and diagnostic aids.
The Glucagen Injection Market segmentation, based on age group, includes Paediatrics and Adults. The Paediatrics category generated the most income (64%). The paediatrics age group has secured the largest market share in the Glucagen Injection market due to the critical need for rapid blood sugar elevation in paediatric emergency situations such as severe hypoglycemia. Glucagen Injections are vital in addressing acute hypoglycemic episodes in children, making them a primary choice for this demographic. The specific requirements for paediatric emergency care and the prevalence of pediatric hypoglycemic incidents have led to the dominance of this age group in the market for Glucagen Injections.
The adult age group is experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to expanding utilization in emergency medical response and diagnostic procedures among adults. The increasing prevalence of conditions requiring rapid blood sugar elevation and the rising use of Glucagen Injections for diagnostic purposes in adult populations have contributed to this notable growth. Additionally, the aging demographic and a greater focus on adult healthcare have further propelled the demand for Glucagen Injections among adults, leading to the highest CAGR in this market segment.
The Glucagen Injection Market segmentation, based on Route of administration, includes Subcutaneous, Intramuscular and Intravenous. The subcutaneous category generated the most income (35.4%). The subcutaneous route of administration has secured the largest market share in the Glucagen Injection market due to its ease of use and effectiveness in delivering rapid blood sugar elevation. This method offers quick absorption and is well-suited for emergency situations, making it the preferred choice for administering Glucagen Injections. The simplicity and swiftness of subcutaneous administration, particularly in urgent hypoglycemic scenarios, have contributed to its dominance in the market for Glucagen Injections.
The intramuscular route of administration is experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to its increasing adoption in emergency medical settings and diagnostic procedures. This route offers rapid absorption and is preferred for its versatility in various clinical scenarios, contributing to its notable growth. The expanding use of intramuscular administration for Glucagen Injections in emergency response and diagnostic applications has led to its substantial CAGR within the market for these critical medical interventions.
The Glucagen Injection Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The online pharmacies category generated the most income (42%). Online pharmacies have secured the largest market share in the Glucagen Injection market due to their convenience, accessibility, and ability to reach a broad customer base. The ease of ordering, coupled with swift delivery services, has made online pharmacies a preferred choice for obtaining critical medications like Glucagen Injections. Additionally, the increasing reliance on online platforms for healthcare products, particularly during the ongoing shift towards digital channels, has contributed to the dominance of online pharmacies in the market for Glucagen Injections.
Hospital pharmacies are experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to the rising demand within hospital settings for emergency care and diagnostic procedures. The crucial role of Glucagen Injections in addressing acute hypoglycemia and supporting various medical imaging and diagnostic processes has led to their increased utilization within hospital pharmacies. This heightened reliance on hospital-based distribution channels for Glucagen Injections has propelled the notable CAGR growth within this segment of the market.
Figure 1: Glucagen Injection Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Glucagen Injection Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America has captured the largest market share in the Glucagen Injection market due to factors such as a high prevalence of diabetes, well-established healthcare infrastructure, and a significant focus on emergency care. The region's advanced healthcare systems, widespread awareness of diabetes management, and accessibility to emergency medications contribute to the dominance of Glucagen. Additionally, the proactive approach toward diabetes education and the large patient population with diabetes in North America solidify its position as a key consumer of Glucagen injections. Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: GLUCAGEN INJECTION MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has captured the second-largest market share in the Glucagen Injection market due to factors such as a substantial diabetic population, well-developed healthcare systems, and a proactive approach to emergency care. The region's robust healthcare infrastructure, coupled with high awareness among healthcare professionals and patients, contributes to the significant use of Glucagen. Additionally, stringent regulatory standards ensure the availability and accessibility of Glucagen, solidifying Europe's position as a substantial consumer of emergency hypoglycemia treatment. Further, the German Glucagen Injection market held the largest market share, and the UK Glucagen Injection market was the fastest growing market in the European region
The Asia Pacific region is growing at the highest Compound Annual Growth Rate (CAGR) in the Glucagen Injection market due to increasing diabetes prevalence, rising healthcare awareness, and improving healthcare infrastructure. The region's large and diverse population, coupled with a growing emphasis on emergency care and diabetes management, contributes to the robust adoption of Glucagen. As healthcare facilities expand and awareness campaigns intensify, the Asia Pacific region demonstrates significant growth potential, positioning it as a key contributor to the increasing CAGR in the Glucagen Injection market. Moreover, China’s Glucagen Injection market held the largest market share, and the Indian Glucagen Injection market was the fastest growing market in the Asia-Pacific region.
Glucagen Injection Key Market Players & Competitive Insights
Leading market players in the Glucagen Injection market are focused on strategic initiatives such as product development, geographic expansion, and collaborations. These companies actively engage in research and development to enhance glucagon formulations and delivery methods. Marketing developments emphasize the importance of Glucagen in diabetes emergency care. Collaborations with healthcare providers and institutions enhance the overall competitiveness. Efforts are directed towards maintaining product quality, meeting regulatory standards, and expanding market reach, ensuring a strong presence in the evolving landscape of the Glucagen Injection market.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Glucagen Injection industry to benefit clients and increase the market sector. In recent years, the Glucagen Injection industry has offered some of the most significant advantages to medicine. Major players in the Glucagen Injection market, including General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., and others, are attempting to increase market demand by investing in research and development operations.
Novo Nordisk is a major player in the Glucagen Injection market, emphasizing its commitment to diabetes care. As a leading pharmaceutical company, Novo Nordisk produces GlucaGen, a glucagon injection used for emergency treatment of severe hypoglycemia in individuals with diabetes. The company's business strategy involves continuous research and development, ensuring product quality, and expanding its global presence. Novo Nordisk's comprehensive approach to diabetes management, including emergency interventions like GlucaGen, solidifies its position in the market. The company's dedication to innovation, patient-centric solutions, and collaborative efforts with healthcare professionals contribute to its significant role in shaping the Glucagen Injection market landscape.
Xeris Pharmaceuticals is a key player in the Glucagen Injection market, known for its innovation in diabetes care. The company specializes in developing and commercializing ready-to-use, liquid-stable glucagon formulations, addressing the critical need for emergency hypoglycemia treatment. Xeris focuses on advancing patient-centric solutions, enhancing the ease of glucagon administration. With a commitment to diabetes management, Xeris' products, including GVOKE HypoPen, offer simplicity and accessibility. The company's strategic emphasis on product development, partnerships, and market expansion positions Xeris Pharmaceuticals as a significant contributor to the evolving landscape of the Glucagen Injection market.
Key Companies in the Glucagen Injection market include
Glucagen Injection Industry Developments
June 2022:Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. have jointly declared a strategic collaboration focused on the development, manufacturing, and commercialization of Liraglutide, encompassing both diabetes and obesity indications. This partnership extends to 17 countries within the Middle East and North Africa region (MENA), including the UAE.
May 2022:The US FDA has granted approval to Eli Lilly and Company for Mounjaro (tirzepatide) injection as an adjunct to diet and exercise, aiming to improve glycemic control in adult patients with type 2 diabetes. Mounjaro, a singular molecule, is a weekly administered glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.24 Billion |
| Market Size 2023 | USD 0.25 Billion |
| Market Size 2032 | USD 0.41 Billion |
| Compound Annual Growth Rate (CAGR) | 5.63% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Application, Age Group, Route of Administration, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novo Nordisk, Eli Lilly and Company, Xeris Pharmaceuticals, Teva Pharmaceutical Industries, Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, LLC. Zealand Pharma A/S., Avalon Pharma Pvt. Ltd, Sanofi and Roche. |
| Key Market Opportunities | · Increase in patient education and awareness |
| Key Market Dynamics | · Increase In Patient Education and Awareness |
Frequently Asked Questions (FAQ) :
The Glucagen Injection Market size was valued at 0.24 Billion in 2022.
The global market is projected to grow at a CAGR of 5.63% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Novo Nordisk, Eli Lilly and Company, Xeris Pharmaceuticals, Teva Pharmaceutical Industries, Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, LLC. Zealand Pharma A/S., Avalon Pharma Pvt. Ltd Company.
The Therapeutic purpose category dominated the market in 2022.
The online pharmacies had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
